Skip to content
Tenfell
Awarded contract
Published 31 Mar 2026

Genome Plasmid

University Of Edinburgh · Scotland

Key facts

Contract value
USN 75,135
Awarded
14 Aug 2025
Procedure
Open procedure
Buyer type
Education

Awarded to

SupplierValue
Indiana UniversityUSN 75,135

Description

We are planning a clinical trial to treat a rare genetic disease that causes progressive dementia in children. Our therapy is based on the following: Autologous haematopoietic stem progenitor cells (HSPCs) are modified ex vivo with a lentiviral vector (LV) to express supraphysiologic levels of a secreted enzyme in myeloid progeny, in essence using gene-modified monocytes/macrophages as a durable and effective vehicle for central nervous system (CNS) enzyme delivery. In order to progress this therapy, we require the following; a plasmid to our specification, produced to FDA, IND ready standard for use in the manufacture of a lentiviral vector for clinical trial. This Plasmid will be delivered directly from the supplier to the University of Edinburgh’s partner in the project, University of California Los Angeles.

Categories (CPV)

Similar open tenders

About University Of Edinburgh

Their tenders, awards, contracts coming up for renewal, decision makers and committee papers.

View buyer profile

Published by the buyer on Public Contracts Scotland (Open Government Licence v3.0). Always read the original notice before responding.